文献速递围术期管理与 ERAS急腹症与外科感染

大型非心脏手术术中白蛋白使用:发生率、机构差异与结局关联

Intraoperative Use of Albumin in Major Noncardiac Surgery: Incidence, Variability, and Association With Outcomes.
PubMed 文献 · Ann Surg · 2022-12-14

基于美国54家医院614,215例大型非心脏手术的回顾性队列分析,术中白蛋白使用率为15.3%且机构间差异显著。倾向评分匹配队列(n=153,218)显示,白蛋白使用与急性肾损伤、净正液体平衡、肺部并发症及30天死亡率风险升高相关。

要点

  • 大型非心脏手术术中白蛋白使用率15.3%,机构间差异显著。
  • 倾向评分匹配后,白蛋白使用与AKI、肺部并发症及30天死亡率升高相关。
  • 白蛋白使用病例多为ASA分级更高、晶体液量更大、失血更多及使用升压药者。

核心结论

  • 大型非心脏手术中静脉白蛋白使用常见且机构间差异显著,并与术后并发症风险增加相关。

研究设计与样本

  • 观察性回顾性队列分析,纳入美国54家医院2014年1月至2020年6月成人全身麻醉下大型非心脏手术614,215例。

主要发现

  • 614,215例大型手术中15.3%使用白蛋白,以等渗白蛋白为主,机构间使用模式差异显著。
  • 使用白蛋白的病例ASA分级更高、晶体液输注量更大、失血量更多且使用升压药。
  • 倾向评分匹配队列(n=153,218)中,白蛋白使用与AKI(aOR 1.24,95%CI 1.20-1.28,P<0.001)相关。
  • 白蛋白使用与严重AKI(aOR 1.45,95%CI 1.34-1.56,P<0.001)及净正液体平衡(aOR 1.18,95%CI 1.16-1.20,P<0.001)相关。
  • 白蛋白使用与肺部并发症(aOR 1.56,95%CI 1.30-1.86,P<0.001)及30天全因死亡率(aOR 1.37,95%CI 1.26-1.49,P<0.001)相关。

临床怎么用

  • 大型非心脏手术中应审慎评估术中白蛋白使用的必要性,尤其对高ASA分级、大失血及大量晶体液输注病例。
  • 白蛋白使用与不良结局相关,提示需关注液体管理策略及术后肾功能、肺部并发症监测。

局限性

  • 观察性回顾性设计,即使倾向评分匹配仍可能存在残余混杂。
  • 仅纳入美国54家医院,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of albumin use during major surgery is unknown, and a dearth of evidence governing its use in major noncardiac surgery has long precluded its standardization in clinical guidelines. OBJECTIVE: In this study, we investigate institutional variation in albumin use among medical centers in the United States during major noncardiac surgery and explore the association of intraoperative albumin administration with important postoperative outcomes. METHODS: The study is an observational retrospective cohort analysis performed among 54 U.S. hospitals in the Multicenter Perioperative Outcomes Group and includes adult patients who underwent major noncardiac surgery under general anesthesia between January 2014 and June 2020. The primary endpoint was the incidence of albumin administration. Secondary endpoints are acute kidney injury (AKI), net-positive fluid balance, pulmonary complications, and 30-day mortality. Albumin-exposed and albumin-unexposed cases were compared within a propensity score-matched cohort to evaluate associations of albumin use with outcomes. RESULTS: Among 614,215 major surgeries, predominantly iso-oncotic albumin was administered in 15.3% of cases and featured significant inter-institutional variability in use patterns. Cases receiving intraoperative albumin involved patients of higher American Society of Anesthesiologists physical status and featured larger infused crystalloid volumes, greater blood loss, and vasopressor use. Overall, albumin was most often administered at high-volume surgery centers with academic affiliation, and within a propensity score-matched cohort (n=153,218), the use of albumin was associated with AKI (aOR 1.24, 95% CI 1.20-1.28, P <0.001), severe AKI (aOR 1.45, 95% CI 1.34-1.56, P <0.001), net-positive fluid balance (aOR 1.18, 95% CI 1.16-1.20, P <0.001), pulmonary complications (aOR 1.56, 95% CI 1.30-1.86, P <0.001), and 30-day all-cause mortality (aOR 1.37, 95% CI 1.26-1.49, P <0.001). CONCLUSIONS: Intravenous albumin is commonly administered among noncardiac surgeries with significant inter-institutional variability in use in the United States. Albumin administration was associated with an increased risk of postoperative complications.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Lazzareschi DV, Fong N, Mavrothalassitis O, et al. Intraoperative Use of Albumin in Major Noncardiac Surgery: Incidence, Variability, and Association With Outcomes. Ann Surg. 2022. PMID: 36521076. doi:10.1097/SLA.0000000000005774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。